Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Confusion, delirium, multiorgan damage hallmarks of COVID-19 in older patients

31 Oct 2020

The novel coronavirus disease (COVID-19) presents as a severe disease in most of the older patients and carries distinctive features, such as multiorgan injury and confusion and delirium, a new study reports.

“The current study emphasizes the need for early identification [and] intensive surveillance leading to appropriate care management of SARS-CoV-2 infection. Preventive strategies to avoid transmission to this particularly vulnerable patient setting still remain in great need,” the researchers said.

From a prospective cohort of 76 older COVID-19 patients (median age, 90 [86–92] years; 55.3 percent female), almost all (97.4 percent; n=74) presented with medical comorbidities, with more than half (64.5 percent; n=49) having three or more. Twenty-two patients died, most of whom were male. The resulting case fatality rate at day 21 was 28.9 percent.

The most common presenting symptoms were asthenia (76.3 percent) and fever (75.0 percent), followed closely by confusion or delirium (71.1 percent). Notably, in two patients, confusion was the only symptom. In addition, 25 percent of the participants had recorded initial falls at disease onset.

In terms of laboratory results, 88.2 percent of the participants had lymphopoenia, while 14.5 percent had thrombocytopoenia. Kidney injury was reported in 9.2 percent (n=7) of the patients. Among nonsurvivors, levels of various biomarkers such as lymphocyte count at nadir, C-reactive protein (CRP), serum creatinine, and albumin were all significantly altered.

However, only nadir lymphocyte count (hazard ratio [HR], 0.186, 95 percent confidence interval [CI], 0.037–0.932) and CRP (HR, 1.012, 95 percent CI, 1.005–1.019) emerged as significant and independent predictors of mortality, according to multivariate Cox proportional hazards analysis.

Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.